To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital

Kanchan, Rohith; Kamoji, Sushruth Guruput; Patil, Malteshgouda N.

doi:10.4172/2155-9554.1000387

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though Rituximab has a high upfront cost but the overall expense in terms of hospital visits and stays, in the duration of the disease, is better as compared to other pulse therapies ( ; thereby reducing the burden of disease. 22…”

Section: Discussionmentioning

confidence: 99%

Rituximab as first line: an advent in pemphigus

et al. 2019

View full text Add to dashboard Cite

<p class="abstract">Rituximab is a newly approved biological wonder drug in pemphigus vulgaris -an autoimmune mucocutaneous blistering disease due to antibodies produced against the epidermal adhesion molecules dsg 1 and dsg 2. The conventional therapy included high dose steroids or immunosuppressants that though effective had significant adverse effects that necessitated an alternate path in treatment. We present a case series of five patients in different clinical scenarios diagnosed with pemphigus vulgaris and treated with Rituximab by RA protocol either sole or in combination with other treatment strategies. Our experience with this drug has paved way to immense possibilities and outcomes that are in favour of using Rituximab as first line option. We have encountered prolonged remission in cases that were treated with Rituximab by Rheumatoid arthritis (RA) protocol. The sustained response has helped in reducing the dose of steroids and other immunosuppressants substantially. These facts are reinforced through our observations. But there is need to standardize the dosage of Rituximab in pemphigus.</p>

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab as first line: an advent in pemphigus

et al. 2019

View full text Add to dashboard Cite

show abstract

Cost Comparative Analysis of Dexamethasone-Cyclophosphamide Pulse Therapy and Rituximab Therapy in Pemphigus in a Government Tertiary Care Hospital in Northern India.

Kaur

Dhillon

2021

ijsr

View full text Add to dashboard Cite

Pemphigus vulgaris is the most common autoimmune blistering disorder and the prevalence varies from 0.18 to 6.96 cases per 1,00,000 population worldwide [3].Pulse therapy with high doses of Corticosterids and Cyclophosphamide (most commonly Dexamethasone Cyclophosphamide Pulse (DCP)) for the treatment of pemphigus remained mainstay therapy for past few decades. Targeted immuno-modulation is becoming popular with advent of biological therapies like Rituximab due to lower side effects but its cost is a limiting factor. There is a little literature available on comparison of cost of these therapies which lead us to compare cost of these therapies. In a country like India where cost is a greater parameter to decide therapy a cost effective therapy carries a better compliance and effectiveness as compared to an expensive therapy like Rituximab. In the study we observed DCPtherapy was three times cheaper than Rituximab

show abstract

To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital

Abstract: Background: Pulsed corticosteroids are the mainstay in management of pemphigus but long term use is associated with numerous side effects. Biologics have shown promising results with minimal adverse effects but are expensive.

Cited by 2 publications

References 8 publications

Rituximab as first line: an advent in pemphigus

Rituximab as first line: an advent in pemphigus

Cost Comparative Analysis of Dexamethasone-Cyclophosphamide Pulse Therapy and Rituximab Therapy in Pemphigus in a Government Tertiary Care Hospital in Northern India.

Contact Info

Product

Resources

About